Company news

C4 Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies

June 13, 2021

C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation

June 6, 2021

C4 Therapeutics to Advance CFT8919, A Selective Degrader of EGFR L858R, Into IND-enabling Studies

May 25, 2021

C4 Therapeutics Appoints Lauren White as Chief Financial Officer

May 19, 2021

C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

May 12, 2021

C4 Therapeutics to Present at Upcoming Investor Conferences

May 11, 2021

C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021

April 9, 2021

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic Malignancies

January 18, 2021

C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022

January 5, 2021

C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results

November 11, 2020

C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

October 5, 2020

C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering

September 30, 2020

← Newer news releases

Decks

The 5 newest of 37 decks. Every deck is listed under its year.